KYOWA-KIRIN
Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, and Grünenthal GmbH (CEO: Gabriel Baertschi), a global, science-based, privately-owned pharmaceutical company, are today announcing they have signed a Joint Venture Collaboration for Kyowa Kirin International's established medicines portfolio. The Joint Venture Collaboration comprises 13 brands across 6 therapeutic areas primarily focused on pain management, including Abstral® and PecFent® for breakthrough cancer pain, Moventig® for opioid-induced constipation, and Adcal-D3® for osteoporosis. The Joint Venture Collaboration is subject to obtaining customary approvals and clearances, including anti-trust and works councils as legally required. Completion of the deal is anticipated for Q2 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221124005096/en/
The total revenues of the portfolio in 2021 were approximately €200 million. The products are marketed through affiliates in seven major European countries and through a network of partners in various additional territories worldwide. Grünenthal has agreed to pay approximately €80 million upfront plus royalties over the term of the collaboration. Grünenthal will make an additional payment upon purchase of the remaining share and the intellectual property (IP) of the portfolio.
“As a leader in pain management, and with our proven track record in growing established brands, we believe we can help even more patients benefit from this unique group of medicines”, said Gabriel Baertschi, Chief Executive Officer, Grünenthal. “This portfolio of established brands matches very well with Grünenthal’s geographical footprint and therapeutic areas.”
Abdul Mullick, President of Kyowa Kirin International said, “Our search for a partner included three key priorities: a team who shares our commitment to patients and to our employees, a partner who is looking to support our growth agenda, and a company with which we can establish a close, collaborative partnership that promises benefits for all our stakeholders while operating at the highest ethical standards. This collaboration will bring a renewed focus, the resources and the commercial infrastructure required to grow the established medicines portfolio to deliver life-changing value to more patients.”
Subject to approval, Grünenthal will own a 51 percent majority share in the new company. Kyowa Kirin will own a 49 percent share and will initially retain the IP related to the portfolio.
Grünenthal intends to purchase the remaining 49 percent share and the IP at the beginning of 2026.
About the portfolio
The portfolio includes medicines that deliver life-changing value for hundreds of thousands of patients. The portfolio is available in seven major European markets through affiliates and in various additional territories worldwide through a network of partners. Key products in the portfolio include Abstral® and PecFent® (Fentanyl) for breakthrough cancer pain, Moventig® (Naloxegol) for opioid-induced constipation and Adcal-D3® (calcium and vitamin D3) for osteoporosis.
About Kyowa Kirin
Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based global specialty pharmaceutical company with a more than 70-year heritage, we apply cutting-edge science, including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork, innovation, and integrity. You can learn more about the business of Kyowa Kirin at: https://www.kyowakirin.com/.
Kyowa Kirin International is a subsidiary of Kyowa Kirin Co., Ltd.
About Grünenthal
Grünenthal is a global leader in pain management and related diseases. As a science-based, fully-integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2021, Grünenthal employed around 4,500 people and achieved sales of € 1.5 bn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221124005096/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Armis Recognized for Innovation; Named to Inc. Best in Business List for the Second Consecutive Year2.12.2025 13:00:00 CET | Press release
Annual list spotlights companies and leaders delivering meaningful results for their industries, customers and future growth Armis, the cyber exposure management & security company, today announced that it has once again been named to Inc.’s Best in Business list, specifically highlighted in the Best in Innovation category for 2025. Inc.’s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made a profound impact on their industries and on society at large. “Armis rapidly innovates and continuously enhances our comprehensive Cyber Exposure Management Platform so that global organizations can proactively protect against cyber threats before there’s any impact,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “Unlike other solutions on the market, Armis addresses the entire lifecycle of managing cyber threats so that security teams no longer reactively respond to breaches. This is a strategic and monumental shift for the indust
Egle Therapeutics Initiates Phase 1 Healthy Volunteer Study of EGL-003, a Next Generation Treg IL-2 Agonist for Atopic Dermatitis2.12.2025 12:32:00 CET | Press release
Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company developing precision medicines that modulate regulatory T cells (Tregs) to restore immune balance, today announced dosing of the first healthy volunteer in the Phase 1 clinical study of EGL-003, an IL‑2⍺-biased mutein designed to selectively activate Tregs while limiting effector T cell stimulation, as a potential treatment for atopic dermatitis. The open-label, multi-center Phase 1 trial begins with a single ascending dose portion in healthy volunteers to rapidly generate foundational safety, pharmacokinetic (PK), and pharmacodynamic (PD) data. These findings will inform dose selection and scheduling for the subsequent multiple ascending dose portion in approximately 40 adults with atopic dermatitis (AD), which will evaluate safety, PK/PD, and early clinical activity versus placebo. Data from both study segments are expected to guide dose selection for a planned Phase 2a trial in AD aimed at establishing clinical pro
AI Takes Center Stage as the Major Threat to Cybersecurity in 20262.12.2025 12:00:00 CET | Press release
Experian releases its 13th Annual Data Breach Industry Forecast highlighting six predictions for 2026 that include several ways AI may have an impact Experian® today released its 2026 Data Breach Industry Forecast, offering a look at the evolving cyber threat landscape. The predictions address how the coming year could usher in a new wave of sophisticated attacks driven by artificial intelligence along with other threats and vulnerabilities including quantum computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202474758/en/ Experian's 2026 Data Breach Industry Forecast Now in its 13th year, the forecast offers six insights into how cybercriminals are leveraging emerging technologies to create more convincing identities, evade detection, and exploit new digital frontiers. From synthetic profiles and autonomous AI agents to shape-shifting malware and even brain-computer interface vulnerabilities, the 2026 predictions p
Buro Happold Signs Landmark Agreement with Expo 2030 Riyadh Company to Deliver Detailed Master Plan and Infrastructure and Public Realm Design for Expo 2030 Riyadh2.12.2025 11:00:00 CET | Press release
Buro Happold, a leading global engineering, design and advisory consultancy, has signed a major contract with Expo 2030 Riyadh Company to serve as the lead design consultant for the detailed master plan and detailed design of public realm, landscape, infrastructure and utilities for Expo 2030 Riyadh and its legacy. This partnership represents a significant step toward delivering an event billed as “An Unprecedented World Expo”. Expo 2030 Riyadh is expected to feature nearly 197 participating countries and attract over 42 million visits to Pavilions covering approximately 6 million sqm. The event will offer a unique opportunity for participants to address shared challenges and showcase pioneering solutions for a sustainable future. Under the agreement, Buro Happold will provide comprehensive design and technical services, including, development of the detailed master plan, including a focus on event requirements and legacy phase elements, detailed design of the infrastructure works, uti
ThetaRay Report Warns Europe’s AML System at ‘Breaking Point’ as New Regulations Make AI Adoption Inevitable2.12.2025 11:00:00 CET | Press release
Study by EU regulatory expert Prof. Andrea Minto and ThetaRay VP Regulatory Affairs Yaron Hazan finds legacy AML tools unfit for Europe’s new regulatory era ThetaRay, a global leader in Cognitive AI financial crime compliance, today released a landmark study on the future of anti-money laundering in Europe. The study warns that Europe’s anti-money laundering (AML) system is approaching structural failure, and that financial institutions will be unable to meet upcoming supervisory expectations without advanced AI-driven monitoring and customer screening systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202058684/en/ Next Generation AML Solutions The report, “Next-Generation AML Solutions: An Analysis of AI-Based Tools vis-à-vis the Reform of the European AML Institutional and Substantive Architecture,” offers some of the most comprehensive examinations to date of how the EU’s sweeping AML reform package and the Artif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom